Skip to main content
Black Health logo Black Health
Cardiovascular Last reviewed:

Atrial Fibrillation

Also known as: A-Fib, AF, AFib, irregular heartbeat

Reviewed by the Black Health editorial team Last reviewed

~2x

stroke and mortality rates in Black patients with A-Fib vs. white patients (ARIC, JAMA Cardiology, 2016)

Overview

Atrial fibrillation (AFib) carries a paradox for Black adults: the clinical diagnosis rate is lower than in White adults, yet Black patients with AFib suffer stroke and death at substantially higher rates.[1] That gap is not a biological inevitability. It reflects delayed diagnosis, undertreated risk factors, and systematic underuse of the medications that prevent stroke. This page explains what AFib is, what the disparities look like, and what evidence-based care looks like for Black adults specifically.

How Atrial Fibrillation affects Black patients

The paradox was first named in print by Soliman and Goff in the Journal of the National Medical Association in 2008 (PMID 18484116) and it has held up across every major U.S. cohort since. In the Atherosclerosis Risk in Communities study (ARIC), the incidence of A-Fib was 8.1 per 1,000 person-years in white participants and 5.8 in Black participants. The same cohort showed stroke rate differences of 10.2 in white patients with A-Fib versus 21.4 in Black patients, and mortality rate differences of 55.9 versus 106.0 (Magnani et al., JAMA Cardiology 2016, PMID 27438320). The REGARDS study confirmed the lower incidence pattern (PMID 27531069), even though Black participants entered the study with more hypertension, more diabetes, and higher BMI, the classic risk factors that should push A-Fib rates up, not down.

Two things are going on at once. The first is underdiagnosis. REGARDS investigators found that only one in three Black participants who had A-Fib on a study ECG knew they had it, compared to roughly six in ten white participants. The odds of awareness were a third (Meschia et al., Stroke 2010). A-Fib is often paroxysmal, meaning it comes and goes, and it gets caught when somebody bothers to look. Black patients are less likely to receive ambulatory rhythm monitoring, less likely to have a primary care relationship dense enough to flag intermittent palpitations, and more likely to first present with the stroke itself.

The second is the anticoagulation gap. Once A-Fib is diagnosed, the stroke-prevention drug should follow within days. It often does not. In the ORBIT-AF II registry, Black patients prescribed anticoagulation were significantly less likely to receive a direct oral anticoagulant (DOAC) and more likely to be kept on warfarin, even after adjusting for clinical and socioeconomic factors (Essien et al., JAMA Cardiology 2018, PMID 30484833). Adjusted odds of receiving a DOAC were 0.63, dropping to 0.73 after socioeconomic adjustment. Black patients who did get a DOAC were more likely to be dosed incorrectly. Warfarin is not equivalent to a DOAC: it requires monthly blood draws, has dozens of food and drug interactions, and the time-in-therapeutic-range is lower in Black patients in nearly every reported series.

The CHA2DS2-VASc score, the calculator clinicians use to decide who needs anticoagulation, is itself part of the problem. Johnson and Magnani argued in the Journal of the American College of Cardiology (PMID 28209231) that the score was derived in cohorts that were overwhelmingly white and European and likely underestimates true stroke risk in Black patients with A-Fib. If a doctor tells you your CHA2DS2-VASc is 1 and you don't need anticoagulation, ask whether that calculator was validated in people who look like you.

Symptoms

  • Palpitations, described as a fluttering, pounding, or galloping in the chest, sometimes only at night or after caffeine
  • Shortness of breath, especially climbing stairs or lying flat
  • Fatigue that is new, persistent, and not explained by sleep or workload
  • Lightheadedness or near-fainting
  • Chest discomfort or pressure
  • A pulse that feels irregular when you press two fingers to your wrist or neck
  • No symptoms at all. Paroxysmal A-Fib can be completely silent and is sometimes first discovered when a smartwatch flags it or after a stroke

When to see a doctor

Call 911 for sudden one-sided weakness, facial droop, slurred speech, sudden severe headache, or sudden vision loss. These are stroke symptoms and time is brain tissue. Go to an emergency department for chest pain, fainting, or a heart rate over 120 that will not slow down. Book a same-week appointment for new palpitations, especially if they last more than a few minutes, recur, or come with shortness of breath. If you already have a diagnosis of hypertension, diabetes, sleep apnea, heart failure, or chronic kidney disease, your background risk for A-Fib is elevated and a single episode of palpitations is worth a 12-lead ECG plus, often, a 2-week ambulatory monitor. Do not let a clinician tell you it is anxiety without running the ECG.

Screening

There is no universal A-Fib screening recommendation for asymptomatic adults from the U.S. Preventive Services Task Force; the 2022 USPSTF statement concluded evidence was insufficient. The 2023 ACC/AHA/ACCP/HRS guideline (Joglar et al., Circulation 2024, PMID 38033089) recommends considering screening in adults 65 and older, particularly those with multiple risk factors. In practice that means a pulse check at every visit, a 12-lead ECG when palpitations are reported, and ambulatory monitoring (Holter, patch monitor, or implantable loop recorder) when symptoms are intermittent. Consumer wearables (Apple Watch, Fitbit, KardiaMobile) have FDA-cleared single-lead ECG features and can catch episodes a clinic ECG misses; a wearable alert should be taken to a clinician, not dismissed.

Treatment overview

Treatment has two tracks that run in parallel. Stroke prevention is the first and the one that bends the mortality curve. For most patients with a CHA2DS2-VASc score of 2 or higher (1 or higher in some scenarios), the 2023 guideline recommends a DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) over warfarin as first line, with warfarin reserved for mechanical heart valves and moderate-to-severe mitral stenosis. Given the documented prescribing disparity (Essien, JAMA Cardiology 2018), a Black patient with A-Fib should specifically ask why a DOAC is or is not being offered, and whether cost or a guideline reason is driving the choice. Patient assistance programs exist for every approved DOAC.

Rhythm and rate control is the second track. Rate control uses beta blockers (metoprolol, carvedilol) or calcium channel blockers (diltiazem, verapamil) to slow conduction at the AV node. Rhythm control uses antiarrhythmic drugs (flecainide, propafenone, amiodarone, dronedarone, sotalol) or catheter ablation. The 2023 guideline upgraded catheter ablation to a Class I recommendation as first-line therapy for symptomatic paroxysmal A-Fib in selected patients, a notable change from prior guidelines. Risk-factor modification (treating hypertension to target, weight loss if BMI is elevated, treating obstructive sleep apnea, reducing alcohol) is now formally part of treatment, not lifestyle advice tacked on at the end.

Questions to ask your doctor

Bring this list to your next appointment.

  1. Based on my CHA2DS2-VASc score, do I qualify for anticoagulation -- and if so, is a DOAC appropriate for me?
  2. Should I be on rate control or rhythm control, or both?
  3. Am I a candidate for catheter ablation, and if not, why not?
  4. How aggressively should I treat my blood pressure to lower AFib risk?
  5. Do I need a Holter monitor or wearable cardiac monitor to check how often I am actually in AFib?
  6. What symptoms should send me to the emergency room?

Find care for atrial fibrillation

Not sure where to start? Describe what you're experiencing and we'll help you find the right kind of care, including a cardiology.

Find care

The numbers

  • The lifetime risk of AFib is approximately 20 percent in African American individuals, compared to 30 to 40 percent in White individuals -- yet Black adults with AFib face approximately double the rate of ischemic or hemorrhagic stroke.[2]
  • Black patients with AFib have a mean CHA2DS2-VASc score of 5.3 versus 4.5 in White patients, meaning they carry a higher baseline stroke risk at the time of diagnosis.[3]
  • Black adults with AFib had lower rates of any oral anticoagulation compared to White adults (adjusted OR 0.84; 95% CI 0.77 to 0.91).[4]
  • Among those who do receive anticoagulation, Black patients are more likely to be prescribed warfarin than a direct oral anticoagulant (DOAC), despite DOACs having a more predictable effect and lower intracranial hemorrhage risk.[1]
  • In the landmark DOAC clinical trials (ARISTOTLE, ROCKET-AF, RE-LY), Black patients represented only 2 percent of the study population -- making the evidence base weaker for the group that most needs it.[1]
  • Black race was associated with 11 percent lower odds of receiving catheter ablation in a nationwide analysis.[1]

What it is

The heart has four chambers. The two upper chambers (atria) are supposed to beat in a coordinated rhythm with the two lower chambers (ventricles). In AFib, the atria fire chaotically -- hundreds of disorganized electrical signals per minute -- causing an irregular and often rapid heartbeat. The disorganized atrial movement allows blood to pool and clot. Those clots can travel to the brain, causing a stroke. Over time, poorly controlled AFib also weakens the heart muscle and can lead to heart failure. AFib may cause palpitations, shortness of breath, fatigue, or lightheadedness -- or no symptoms at all, which is part of why it is underdetected.[2]

Why it is different for Black patients

The lower clinical prevalence of AFib in Black adults has long been called a paradox, and new research suggests the gap is partly artifactual. Studies using unbiased arrhythmia detection (continuous monitoring rather than clinician-ordered ECGs) show prevalence rates more similar across racial groups than clinically diagnosed rates suggest -- meaning AFib may be underdetected in Black patients, not truly rarer.[5]

When AFib is diagnosed in Black adults, the risk factor profile looks different. The Jackson Heart Study identified hypertension, obesity, and current smoking as the primary modifiable drivers of incident AFib in Black adults, with hypertension and heart failure carrying the largest hazard ratios (HR 3.20 for history of heart failure; HR 1.23 per 20 mmHg increase in systolic blood pressure).[5] These are conditions that have their own racial disparities in control rates, which compounds the AFib risk.

On the treatment side, the underrepresentation of Black patients in DOAC trials leaves clinicians without race-specific efficacy data at the moment of prescribing -- a structural problem that guidelines now explicitly acknowledge. The 2023 ACC/AHA/ACCP/HRS Guideline for AFib states that stroke-risk reduction therapies should be "equitably offered" regardless of race, ethnicity, or social determinants of health.[2]

Treatment, plainly

AFib management has three goals: controlling the heart rate, restoring or maintaining normal rhythm where appropriate, and preventing stroke.

Rate control means slowing the ventricular response so the heart does not beat dangerously fast even when the atria are firing irregularly. Beta-blockers and calcium channel blockers are the primary agents. Rate control is appropriate for most patients, especially those who are older or have few symptoms.

Rhythm control means trying to restore and keep a normal sinus rhythm -- either with antiarrhythmic medications (flecainide, amiodarone, dofetilide) or with catheter ablation, a procedure that destroys the abnormal electrical pathways. The 2023 guidelines note that early rhythm control can reduce cardiovascular events and may improve quality of life, particularly when low AFib burden is achieved. Black patients are significantly less likely to be referred for catheter ablation, which is a documented gap in equitable care.

Stroke prevention is the most critical piece for Black adults, given the elevated stroke rates. The 2023 guidelines recommend anticoagulation for patients with a CHA2DS2-VASc score of 2 or higher in men and 3 or higher in women. DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin in most non-valvular AFib because they have more predictable pharmacology, require no regular blood monitoring, and carry lower intracranial hemorrhage risk. If you are currently on warfarin and have not had a conversation about switching to a DOAC, that conversation is worth having.

Risk factor management is not optional. Controlling blood pressure aggressively, treating obesity, stopping smoking, and managing sleep apnea all reduce AFib burden and stroke risk -- and these are areas where primary care engagement matters as much as the cardiology visit.

How to find care

Sources

  1. Racial and ethnic disparities in the management of risk factors in individuals with atrial fibrillation: A narrative review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12731936/
  2. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11104284/
  3. Racial disparities and trends in anticoagulant use among ambulatory care patients with atrial fibrillation and atrial flutter in the United States from 2007-2019. medRxiv. https://www.medrxiv.org/content/10.1101/2024.06.14.24308960.full.pdf
  4. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke / AHA Journals. https://www.ahajournals.org/doi/10.1161/STROKEAHA.107.508580
  5. Atrial fibrillation in an African-American cohort: The Jackson Heart Study. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC6153048/
  6. Resting Heart Rate and Incident Atrial Fibrillation in Black Adults in the Jackson Heart Study. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825470
  7. Socioeconomic status and burden of atrial fibrillation hospitalizations among Black US adults: A fifteen-year analysis. ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0146280623001548

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Medical disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. If you are experiencing a medical emergency, call 911 or your local emergency number immediately.

Share:
Find a Black doctor near you